<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-28375" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Physiology, Renin Angiotensin System</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Fountain</surname>
            <given-names>John H.</given-names>
          </name>
          <aff>SUNY Upstate Medical University</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Kaur</surname>
            <given-names>Jasleen</given-names>
          </name>
          <aff>HealthPartners, Minneapolis</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Lappin</surname>
            <given-names>Sarah L.</given-names>
          </name>
          <aff>Upstate University Hospital</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>John Fountain declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Jasleen Kaur declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Sarah Lappin declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>12</day>
          <month>3</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-28375.s1" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>The renin-angiotensin-aldosterone system (RAAS) is a critical regulator of&#x000a0;blood volume, electrolyte balance, and systemic vascular resistance. While the baroreceptor reflex responds short term to decreased arterial pressure, the RAAS is responsible for acute and chronic alterations. The classical understanding&#x000a0;of&#x000a0;RAAS is that it comprises three significant compounds: renin, angiotensin II, and aldosterone.<xref ref-type="bibr" rid="article-28375.r1">[1]</xref><xref ref-type="bibr" rid="article-28375.r2">[2]</xref>&#x000a0;These three compounds elevate arterial pressure in response to decreased renal blood pressure, salt delivery to the distal convoluted tubule, and&#x000a0;beta-agonism. The understanding of RAAS has expanded tremendously due to discoveries of newer system components over the last few decades. The discussion in this article will be limited to the components of the classical pathway of the renin-angiotensin-aldosterone system (see&#x000a0;<bold>Figure.</bold> Renin-Angiotensin&#x000a0;System,&#x000a0;Classical&#x000a0;View).</p>
      </sec>
      <sec id="article-28375.s2" sec-type="Organ Systems Involved">
        <title>Organ Systems Involved</title>
        <p>The renin-angiotensin-aldosterone system is ubiquitous with the involvement of multiple organ systems, especially the kidneys, lungs, systemic vasculature, adrenal cortex, and brain.<xref ref-type="bibr" rid="article-28375.r3">[3]</xref></p>
      </sec>
      <sec id="article-28375.s3" sec-type="Function">
        <title>Function</title>
        <p>The renin-angiotensin-aldosterone system is a crucial mediator of cardiac, vascular, and renal physiology through the regulation of vascular tone and salt and water homeostasis.&#x000a0;</p>
        <p>In addition to the main physiological functions, the RAAS has a significant role in the pathophysiological conditions of hypertension, heart failure, other cardiovascular diseases, and renal diseases.<xref ref-type="bibr" rid="article-28375.r4">[4]</xref><xref ref-type="bibr" rid="article-28375.r5">[5]</xref>&#x000a0;Blockade of the overactivation of RAAS by various medications has been shown to improve outcomes in various cardiovascular and renal diseases.</p>
      </sec>
      <sec id="article-28375.s4" sec-type="Mechanism">
        <title>Mechanism</title>
        <p>
<bold>Renin</bold>
</p>
        <p>The juxtaglomerular (JG) cells, present within the afferent arterioles of the kidney, contain prorenin. Activation of JG cells causes the cleavage of prorenin to renin. The activation of prorenin occurs in the kidney by enzymes like proconvertase 1 and cathepsin B.<xref ref-type="bibr" rid="article-28375.r6">[6]</xref><xref ref-type="bibr" rid="article-28375.r7">[7]</xref>&#x000a0;Mature renin is stored in the granules of the JG cells and released into circulation by&#x000a0;four main stimuli:&#x000a0;<xref ref-type="bibr" rid="article-28375.r8">[8]</xref><xref ref-type="bibr" rid="article-28375.r9">[9]</xref><xref ref-type="bibr" rid="article-28375.r10">[10]</xref>&#x000a0;</p>
        <list list-type="order">
          <list-item>
            <p>Changes in renal perfusion perceived by the pressure transducer mechanism in afferent arterioles (sense stretch from the mechanoreceptors of the arteriolar wall)</p>
          </list-item>
          <list-item>
            <p>Delivery of sodium and chloride to the distal convoluted tubule (DCT) that is sensed by the macula densa</p>
          </list-item>
          <list-item>
            <p>Increased beta-sympathetic flow acting through the beta-1 adrenergic receptors, particularly in the upright posture</p>
          </list-item>
          <list-item>
            <p>Negative feedback from humoral factors like angiotensin I, potassium (renin release is increased by hypokalemia and decreased by hyperkalemia), and ANP (atrial natriuretic peptide)</p>
          </list-item>
        </list>
        <p>Therefore, conditions leading to decreased renal perfusion and reduced tubular sodium content lead to renin enzyme release into the bloodstream. The half-life of renin activity in circulation is 10-15 minutes.<xref ref-type="bibr" rid="article-28375.r11">[11]</xref>&#x000a0;Renin is the rate-limiting enzyme in RAAS.<xref ref-type="bibr" rid="article-28375.r12">[12]</xref></p>
        <p>
<bold>Angiotensinogen</bold>
</p>
        <p>This molecule is primarily synthesized and constitutively secreted by the liver. Renin cleaves the N-terminal of angiotensinogen and leads to the formation of angiotensin I.</p>
        <p>
<bold>Angiotensin I</bold>
</p>
        <p>This peptide does not have any known biological activity.<xref ref-type="bibr" rid="article-28375.r13">[13]</xref></p>
        <p>
<bold>Angiotensin-Converting Enzyme (ACE)</bold>
</p>
        <p>This enzyme is expressed on&#x000a0;plasma membranes of vascular endothelial cells,&#x000a0;primarily in the pulmonary circulation.<xref ref-type="bibr" rid="article-28375.r14">[14]</xref>&#x000a0;It cleaves the two amino acids from the C-terminal of angiotensin I to make the peptide angiotensin II.</p>
        <p>
<bold>Angiotensin II</bold>
</p>
        <p>ACE generates angiotensin II by cleaving the two amino acids at the C-terminal of angiotensin I. Angiotensin II is the&#x000a0;primary mediator of the physiologic effects of RAAS, including blood pressure, volume regulation, and aldosterone secretion.<xref ref-type="bibr" rid="article-28375.r15">[15]</xref>&#x000a0;The half-life of angiotensin II in circulation is very short, less than 60 seconds.<xref ref-type="bibr" rid="article-28375.r16">[16]</xref>&#x000a0;Peptidases degrade it into angiotensin III and IV. Angiotensin III has been shown to have 100% of the aldosterone-stimulating effect of angiotensin II but 40% of the pressor effects, while angiotensin IV has further decreased the systemic effect.<xref ref-type="bibr" rid="article-28375.r17">[17]</xref></p>
        <p>The physiological effects of angiotensin II on extracellular volume and blood pressure regulation are mediated in&#x000a0;five ways:</p>
        <list list-type="order">
          <list-item>
            <p>Vasoconstriction by contraction of the vascular smooth muscle in the arterioles<xref ref-type="bibr" rid="article-28375.r18">[18]</xref></p>
          </list-item>
          <list-item>
            <p>Aldosterone secretion from the adrenal cortex in the zona glomerulosa.<xref ref-type="bibr" rid="article-28375.r18">[18]</xref><xref ref-type="bibr" rid="article-28375.r19">[19]</xref>This is mediated through the transcription of CYP11B2 (aldosterone synthase)<xref ref-type="bibr" rid="article-28375.r20">[20]</xref></p>
          </list-item>
          <list-item>
            <p>Increase sodium reabsorption through increased activity of the Na-H antiporter in the proximal convoluted tubule (PCT)<xref ref-type="bibr" rid="article-28375.r21">[21]</xref></p>
          </list-item>
          <list-item>
            <p>Increasing sympathetic outflow from the central nervous system<xref ref-type="bibr" rid="article-28375.r22">[22]</xref></p>
          </list-item>
          <list-item>
            <p>Release of vasopressin from the hypothalamus<xref ref-type="bibr" rid="article-28375.r23">[23]</xref></p>
          </list-item>
        </list>
        <p>Angiotensin II is also implicated in many pathophysiological states and is known to induce oxidative stress, vascular smooth muscle contraction, endothelial dysfunction, fibrosis, and hypertrophic, anti-apoptotic, and pro-mitogenic effects.<xref ref-type="bibr" rid="article-28375.r24">[24]</xref><xref ref-type="bibr" rid="article-28375.r25">[25]</xref><xref ref-type="bibr" rid="article-28375.r26">[26]</xref>&#x000a0;Angiotensin II has been implicated in the pathogenesis of hypertension, atherosclerotic disease, heart failure, and kidney disease through these effects.<xref ref-type="bibr" rid="article-28375.r27">[27]</xref><xref ref-type="bibr" rid="article-28375.r28">[28]</xref><xref ref-type="bibr" rid="article-28375.r29">[29]</xref><xref ref-type="bibr" rid="article-28375.r30">[30]</xref></p>
        <p>The physiological and pathophysiological effects of angiotensin II are mediated by two types of&#x000a0;receptors: type 1 and type 2.<xref ref-type="bibr" rid="article-28375.r31">[31]</xref>&#x000a0;These receptors have different and often opposing physiological responses.<xref ref-type="bibr" rid="article-28375.r32">[32]</xref></p>
        <p>
<bold>Angiotensin II Type 1 Receptor (AT1-R)</bold>
</p>
        <p>AT1-R is a G-protein coupled receptor.<xref ref-type="bibr" rid="article-28375.r33">[33]</xref>&#x000a0;It is widely distributed in many cell types, including the heart, vasculature, kidney, adrenal glands, pituitary, and central nervous system.<xref ref-type="bibr" rid="article-28375.r34">[34]</xref><xref ref-type="bibr" rid="article-28375.r35">[35]</xref><xref ref-type="bibr" rid="article-28375.r36">[36]</xref><xref ref-type="bibr" rid="article-28375.r37">[37]</xref>&#x000a0;Angiotensin II mediates its physiological effects of vasoconstriction and sodium and water reabsorption through the AT1-R.<xref ref-type="bibr" rid="article-28375.r38">[38]</xref>&#x000a0; In pathogenic states, the activation of the AT1-R leads to&#x000a0;inflammation, fibrosis, oxidative stress, tissue remodeling, and increased blood pressure.<xref ref-type="bibr" rid="article-28375.r39">[39]</xref>&#x000a0;The dysregulation of this&#x000a0;receptor is central to the pathophysiology of cardiac and renal diseases.<xref ref-type="bibr" rid="article-28375.r38">[38]</xref><xref ref-type="bibr" rid="article-28375.r40">[40]</xref><xref ref-type="bibr" rid="article-28375.r41">[41]</xref></p>
        <p>
<bold>Angiotensin II Type 2 Receptor (AT2-R)</bold>
</p>
        <p>AT2-R is a G-protein coupled receptor.<xref ref-type="bibr" rid="article-28375.r33">[33]</xref>&#x000a0;It is&#x000a0;mainly expressed in fetal tissues,&#x000a0;and expression decreases in adulthood.<xref ref-type="bibr" rid="article-28375.r42">[42]</xref><xref ref-type="bibr" rid="article-28375.r32">[32]</xref>&#x000a0;In adults, it is&#x000a0;distributed in the heart, kidney, adrenal glands, and brain.<xref ref-type="bibr" rid="article-28375.r43">[43]</xref><xref ref-type="bibr" rid="article-28375.r44">[44]</xref><xref ref-type="bibr" rid="article-28375.r45">[45]</xref>&#x000a0;AT2-R mediates the opposing and protective effects of&#x000a0;angiotensin II via the AT1-R. These actions&#x000a0;inhibit inflammation, fibrosis, and central sympathetic outflow and cause vasodilation.<xref ref-type="bibr" rid="article-28375.r46">[46]</xref><xref ref-type="bibr" rid="article-28375.r47">[47]</xref>&#x000a0;Stimulation of the AT2-R by&#x000a0;angiotensin II leads to vasodilation and natriuresis, opposite to the vasoconstriction and anti-natriuresis caused by&#x000a0;angiotensin&#x000a0;II via the AT1-R.<xref ref-type="bibr" rid="article-28375.r48">[48]</xref><xref ref-type="bibr" rid="article-28375.r32">[32]</xref><xref ref-type="bibr" rid="article-28375.r49">[49]</xref></p>
        <p>
<bold>Aldosterone</bold>
</p>
        <p>Aldosterone is synthesized primarily in the zona glomerulosa of the adrenal cortex. The synthesis and secretion of this hormone are primarily regulated by angiotensin II, ACTH, and extracellular potassium concentration.<xref ref-type="bibr" rid="article-28375.r50">[50]</xref><xref ref-type="bibr" rid="article-28375.r51">[51]</xref>&#x000a0;The effects of aldosterone are mediated through nuclear cytosolic receptors.<xref ref-type="bibr" rid="article-28375.r52">[52]</xref>&#x000a0;The half-life of aldosterone in plasma is less than 20 minutes.<xref ref-type="bibr" rid="article-28375.r53">[53]</xref>&#x000a0;</p>
        <p>Aldosterone mediates its effects on electrolyte and renal&#x000a0;homeostasis by binding to the MR receptors on principal epithelial cells in the renal cortical collecting duct. Sodium is reabsorbed via the ENaC (epithelial sodium channel) on the apical membranes of principal cells in the collecting tubules. Aldosterone leads to increased concentrations of ENaC channels at the apical membrane,&#x000a0;resulting in increased sodium reabsorption.<xref ref-type="bibr" rid="article-28375.r53">[53]</xref><xref ref-type="bibr" rid="article-28375.r54">[54]</xref>&#x000a0;Na-K ATPase activation at the basolateral membrane of apical cells occurs by the effect of aldosterone.<xref ref-type="bibr" rid="article-28375.r55">[55]</xref>&#x000a0;This leads to sodium transport in the extracellular space and increases potassium uptake in the apical cells. Aldosterone also influences salt and water homeostasis by regulating thirst and salt appetite via the mineralocorticoid receptors present in various regions of the brain.<xref ref-type="bibr" rid="article-28375.r56">[56]</xref><xref ref-type="bibr" rid="article-28375.r57">[57]</xref><xref ref-type="bibr" rid="article-28375.r58">[58]</xref><xref ref-type="bibr" rid="article-28375.r59">[59]</xref></p>
      </sec>
      <sec id="article-28375.s5" sec-type="Clinical Significance">
        <title>Clinical Significance</title>
        <p>Overactivation of the renin-angiotensin-aldosterone system has been implicated in the pathogenesis of various cardiovascular and renal diseases.<xref ref-type="bibr" rid="article-28375.r60">[60]</xref><xref ref-type="bibr" rid="article-28375.r61">[61]</xref><xref ref-type="bibr" rid="article-28375.r62">[62]</xref>&#x000a0;RAAS is also implicated in the pathogenesis of primary hypertension.<xref ref-type="bibr" rid="article-28375.r63">[63]</xref><xref ref-type="bibr" rid="article-28375.r64">[64]</xref>&#x000a0;This has been proven by using medications that block the RAAS at different steps.&#x000a0;</p>
        <p>Overactivation of the RAAS is also implicated in the development of secondary hypertension due to primary hyperaldosteronism. Primary hyperaldosteronism is the excess aldosterone production either by an adrenal adenoma (Conn syndrome) or bilateral adrenal hyperplasia producing excess aldosterone.<xref ref-type="bibr" rid="article-28375.r65">[65]</xref>&#x000a0;These patients have suppressed renin, and elevated aldosterone levels, often with hypokalemia.<xref ref-type="bibr" rid="article-28375.r65">[65]</xref>&#x000a0;Primary hyperaldosteronism remains an under-recognized condition with excess cardiovascular and renal morbidity and mortality.<xref ref-type="bibr" rid="article-28375.r66">[66]</xref>&#x000a0;All patients with resistant hypertension should be screened for this condition for early diagnosis. Early diagnosis and timely management can lead to improved outcomes.</p>
        <p>Medications targeting the renin-angiotensin-aldosterone system include:</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Direct Renin Inhibitor:</bold>&#x000a0;Aliskiren has not improved renal or cardiovascular outcomes in patients with type 2 diabetes.<xref ref-type="bibr" rid="article-28375.r67">[67]</xref><xref ref-type="bibr" rid="article-28375.r68">[68]</xref>&#x000a0;The use of these agents remains uncommon in clinical practice due to the lack of benefit noted from clinical trials.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Angiotensin-Converting Enzyme inhibitors (ACE-i):</bold>&#x000a0;Commonly used agents include lisinopril, captopril, ramipril, enalapril, fosinopril, and benazepril. These are used as first-line agents for the management of hypertension. These agents&#x000a0;have improved cardiovascular (CV) outcomes, including reduced hospitalizations for heart failure and CV mortality.<xref ref-type="bibr" rid="article-28375.r69">[69]</xref><xref ref-type="bibr" rid="article-28375.r70">[70]</xref>&#x000a0;These agents have been shown to improve certain kidney outcomes, such as reducing&#x000a0;microalbuminuria and slowing the progression of kidney disease, even in patients with type 2 diabetes.<xref ref-type="bibr" rid="article-28375.r71">[71]</xref><xref ref-type="bibr" rid="article-28375.r72">[72]</xref><xref ref-type="bibr" rid="article-28375.r73">[73]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Angiotensin Receptor Blockers (ARB):</bold>&#x000a0;Commonly used agents include valsartan, candesartan, irbesartan, olmesartan, and telmisartan. These are used as first-line agents for the management of hypertension. Multiple agents have been shown to improve cardiovascular (CV) outcomes, including reduced heart failure and CV mortality hospitalizations.<xref ref-type="bibr" rid="article-28375.r74">[74]</xref><xref ref-type="bibr" rid="article-28375.r75">[75]</xref><xref ref-type="bibr" rid="article-28375.r76">[76]</xref> These agents have been shown to improve certain kidney outcomes,&#x000a0;such as reducing&#x000a0;microalbuminuria and slowing the progression of kidney disease, even in patients with type 2 diabetes.<xref ref-type="bibr" rid="article-28375.r77">[77]</xref><xref ref-type="bibr" rid="article-28375.r78">[78]</xref><xref ref-type="bibr" rid="article-28375.r79">[79]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Mineralocorticoid Receptor Antagonists (MRA):</bold>&#x000a0;Spironolactone, eplerenone, and finerenone have improved outcomes in patients with a history of heart failure. Spironolactone and eplerenone have been shown to reduce hospitalizations and mortality in patients with heart failure with reduced ejection fraction.<xref ref-type="bibr" rid="article-28375.r80">[80]</xref><xref ref-type="bibr" rid="article-28375.r81">[81]</xref>&#x000a0;Finerenone has been demonstrated to reduce hospitalizations due to heart failure and improve kidney outcomes in patients with diabetic kidney disease.<xref ref-type="bibr" rid="article-28375.r82">[82]</xref><xref ref-type="bibr" rid="article-28375.r83">[83]</xref>&#x000a0;These medications are the first-line agents for use in medically treated cases of primary hyperaldosteronism.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Aldosterone Synthase Blocker:</bold>&#x000a0;Baxdrostat, a selective aldosterone synthase inhibitor, has shown promising results in patients with resistant hypertension in a recent phase 2 clinical trial with dose-dependent reductions in blood pressure.<xref ref-type="bibr" rid="article-28375.r84">[84]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Blockers of ENaC:&#x000a0;</bold>Amiloride and triamterene. These do not have any effect on the mineralocorticoid receptor.</p>
          </list-item>
        </list>
        <p>These agents result in a reduction in&#x000a0;vasoconstriction and improved renal perfusion.<xref ref-type="bibr" rid="article-28375.r85">[85]</xref>&#x000a0;Blockade of components of RAAS also leads to decreased inflammation, hypertrophy, and fibrosis.<xref ref-type="bibr" rid="article-28375.r86">[86]</xref><xref ref-type="bibr" rid="article-28375.r87">[87]</xref>&#x000a0;This results in a reduction in tissue remodeling in the cardiac and renal tissues.</p>
      </sec>
      <sec id="article-28375.s6">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=28375&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=28375">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/28375/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=28375">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-28375.s7">
        <fig id="article-28375.image.f1" position="float" orientation="portrait">
          <caption>
            <p>Renin-Angiotensin System, Classical View. ACE: Angiotensin-converting enzyme. AT1-R: Angiotensin II type 1 receptor. Contributed by J Kaur, MD&#x000a0;</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Renin-angiotensin__system___Classic__view" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-28375.s8">
        <title>References</title>
        <ref id="article-28375.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Almutlaq</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Alamro</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Alroqi</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Barhoumi</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Classical and Counter-Regulatory Renin-Angiotensin System: Potential Key Roles in COVID-19 Pathophysiology.</article-title>
            <source>CJC Open</source>
            <year>2021</year>
            <month>Aug</month>
            <volume>3</volume>
            <issue>8</issue>
            <fpage>1060</fpage>
            <page-range>1060-1074</page-range>
            <pub-id pub-id-type="pmid">33875979</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28375.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wu</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>Mohammadmoradi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>JZ</given-names>
              </name>
              <name>
                <surname>Sawada</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Daugherty</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lu</surname>
                <given-names>HS</given-names>
              </name>
            </person-group>
            <article-title>Renin-Angiotensin System and Cardiovascular Functions.</article-title>
            <source>Arterioscler Thromb Vasc Biol</source>
            <year>2018</year>
            <month>Jul</month>
            <volume>38</volume>
            <issue>7</issue>
            <fpage>e108</fpage>
            <page-range>e108-e116</page-range>
            <pub-id pub-id-type="pmid">29950386</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28375.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Santos</surname>
                <given-names>RAS</given-names>
              </name>
              <name>
                <surname>Oudit</surname>
                <given-names>GY</given-names>
              </name>
              <name>
                <surname>Verano-Braga</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Canta</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Steckelings</surname>
                <given-names>UM</given-names>
              </name>
              <name>
                <surname>Bader</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>The renin-angiotensin system: going beyond the classical paradigms.</article-title>
            <source>Am J Physiol Heart Circ Physiol</source>
            <year>2019</year>
            <month>May</month>
            <day>01</day>
            <volume>316</volume>
            <issue>5</issue>
            <fpage>H958</fpage>
            <page-range>H958-H970</page-range>
            <pub-id pub-id-type="pmid">30707614</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28375.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Engeli</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Negrel</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Sharma</surname>
                <given-names>AM</given-names>
              </name>
            </person-group>
            <article-title>Physiology and pathophysiology of the adipose tissue renin-angiotensin system.</article-title>
            <source>Hypertension</source>
            <year>2000</year>
            <month>Jun</month>
            <volume>35</volume>
            <issue>6</issue>
            <fpage>1270</fpage>
            <page-range>1270-7</page-range>
            <pub-id pub-id-type="pmid">10856276</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28375.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Atlas</surname>
                <given-names>SA</given-names>
              </name>
            </person-group>
            <article-title>The renin-angiotensin aldosterone system: pathophysiological role and pharmacologic inhibition.</article-title>
            <source>J Manag Care Pharm</source>
            <year>2007</year>
            <month>Oct</month>
            <volume>13</volume>
            <issue>8 Suppl B</issue>
            <fpage>9</fpage>
            <page-range>9-20</page-range>
            <pub-id pub-id-type="pmid">17970613</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28375.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Reudelhuber</surname>
                <given-names>TL</given-names>
              </name>
              <name>
                <surname>Ramla</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Chiu</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Mercure</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Seidah</surname>
                <given-names>NG</given-names>
              </name>
            </person-group>
            <article-title>Proteolytic processing of human prorenin in renal and non-renal tissues.</article-title>
            <source>Kidney Int</source>
            <year>1994</year>
            <month>Dec</month>
            <volume>46</volume>
            <issue>6</issue>
            <fpage>1522</fpage>
            <page-range>1522-4</page-range>
            <pub-id pub-id-type="pmid">7699995</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28375.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Neves</surname>
                <given-names>FA</given-names>
              </name>
              <name>
                <surname>Duncan</surname>
                <given-names>KG</given-names>
              </name>
              <name>
                <surname>Baxter</surname>
                <given-names>JD</given-names>
              </name>
            </person-group>
            <article-title>Cathepsin B is a prorenin processing enzyme.</article-title>
            <source>Hypertension</source>
            <year>1996</year>
            <month>Mar</month>
            <volume>27</volume>
            <issue>3 Pt 2</issue>
            <fpage>514</fpage>
            <page-range>514-7</page-range>
            <pub-id pub-id-type="pmid">8613195</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28375.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schweda</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Friis</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Wagner</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Skott</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Kurtz</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Renin release.</article-title>
            <source>Physiology (Bethesda)</source>
            <year>2007</year>
            <month>Oct</month>
            <volume>22</volume>
            <fpage>310</fpage>
            <page-range>310-9</page-range>
            <pub-id pub-id-type="pmid">17928544</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28375.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kurtz</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Control of renin synthesis and secretion.</article-title>
            <source>Am J Hypertens</source>
            <year>2012</year>
            <month>Aug</month>
            <volume>25</volume>
            <issue>8</issue>
            <fpage>839</fpage>
            <page-range>839-47</page-range>
            <pub-id pub-id-type="pmid">22237158</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28375.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kurtz</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Renin release: sites, mechanisms, and control.</article-title>
            <source>Annu Rev Physiol</source>
            <year>2011</year>
            <volume>73</volume>
            <fpage>377</fpage>
            <page-range>377-99</page-range>
            <pub-id pub-id-type="pmid">20936939</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28375.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Skrabal</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Half-life of plasma renin activity in normal subjects and in malignant hypertension.</article-title>
            <source>Klin Wochenschr</source>
            <year>1974</year>
            <month>Dec</month>
            <day>15</day>
            <volume>52</volume>
            <issue>24</issue>
            <fpage>1173</fpage>
            <page-range>1173-4</page-range>
            <pub-id pub-id-type="pmid">4456013</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28375.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>SKEGGS</surname>
                <given-names>LT</given-names>
              </name>
              <name>
                <surname>KAHN</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>LENTZ</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>SHUMWAY</surname>
                <given-names>NP</given-names>
              </name>
            </person-group>
            <article-title>The preparation, purification, and amino acid sequence of a polypeptide renin substrate.</article-title>
            <source>J Exp Med</source>
            <year>1957</year>
            <month>Sep</month>
            <day>01</day>
            <volume>106</volume>
            <issue>3</issue>
            <fpage>439</fpage>
            <page-range>439-53</page-range>
            <pub-id pub-id-type="pmid">13463253</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28375.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Laghlam</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Jozwiak</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Nguyen</surname>
                <given-names>LS</given-names>
              </name>
            </person-group>
            <article-title>Renin-Angiotensin-Aldosterone System and Immunomodulation: A State-of-the-Art Review.</article-title>
            <source>Cells</source>
            <year>2021</year>
            <month>Jul</month>
            <day>13</day>
            <volume>10</volume>
            <issue>7</issue>
            <pub-id pub-id-type="pmid">34359936</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28375.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Studdy</surname>
                <given-names>PR</given-names>
              </name>
              <name>
                <surname>Lapworth</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Bird</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Angiotensin-converting enzyme and its clinical significance--a review.</article-title>
            <source>J Clin Pathol</source>
            <year>1983</year>
            <month>Aug</month>
            <volume>36</volume>
            <issue>8</issue>
            <fpage>938</fpage>
            <page-range>938-47</page-range>
            <pub-id pub-id-type="pmid">6308066</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28375.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Guo</surname>
                <given-names>DF</given-names>
              </name>
              <name>
                <surname>Sun</surname>
                <given-names>YL</given-names>
              </name>
              <name>
                <surname>Hamet</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Inagami</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>The angiotensin II type 1 receptor and receptor-associated proteins.</article-title>
            <source>Cell Res</source>
            <year>2001</year>
            <month>Sep</month>
            <volume>11</volume>
            <issue>3</issue>
            <fpage>165</fpage>
            <page-range>165-80</page-range>
            <pub-id pub-id-type="pmid">11642401</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28375.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>van Kats</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>de Lannoy</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Jan Danser</surname>
                <given-names>AH</given-names>
              </name>
              <name>
                <surname>van Meegen</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Verdouw</surname>
                <given-names>PD</given-names>
              </name>
              <name>
                <surname>Schalekamp</surname>
                <given-names>MA</given-names>
              </name>
            </person-group>
            <article-title>Angiotensin II type 1 (AT1) receptor-mediated accumulation of angiotensin II in tissues and its intracellular half-life in vivo.</article-title>
            <source>Hypertension</source>
            <year>1997</year>
            <month>Jul</month>
            <volume>30</volume>
            <issue>1 Pt 1</issue>
            <fpage>42</fpage>
            <page-range>42-9</page-range>
            <pub-id pub-id-type="pmid">9231819</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28375.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yatabe</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Yoneda</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Yatabe</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Watanabe</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Felder</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Jose</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Sanada</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Angiotensin III stimulates aldosterone secretion from adrenal gland partially via angiotensin II type 2 receptor but not angiotensin II type 1 receptor.</article-title>
            <source>Endocrinology</source>
            <year>2011</year>
            <month>Apr</month>
            <volume>152</volume>
            <issue>4</issue>
            <fpage>1582</fpage>
            <page-range>1582-8</page-range>
            <pub-id pub-id-type="pmid">21303953</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28375.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Harrison-Bernard</surname>
                <given-names>LM</given-names>
              </name>
            </person-group>
            <article-title>The renal renin-angiotensin system.</article-title>
            <source>Adv Physiol Educ</source>
            <year>2009</year>
            <month>Dec</month>
            <volume>33</volume>
            <issue>4</issue>
            <fpage>270</fpage>
            <page-range>270-4</page-range>
            <pub-id pub-id-type="pmid">19948673</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28375.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gupta</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Franco-Saenz</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Mulrow</surname>
                <given-names>PJ</given-names>
              </name>
            </person-group>
            <article-title>Locally generated angiotensin II in the adrenal gland regulates basal, corticotropin-, and potassium-stimulated aldosterone secretion.</article-title>
            <source>Hypertension</source>
            <year>1995</year>
            <month>Mar</month>
            <volume>25</volume>
            <issue>3</issue>
            <fpage>443</fpage>
            <page-range>443-8</page-range>
            <pub-id pub-id-type="pmid">7875770</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28375.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nogueira</surname>
                <given-names>EF</given-names>
              </name>
              <name>
                <surname>Xing</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Morris</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Rainey</surname>
                <given-names>WE</given-names>
              </name>
            </person-group>
            <article-title>Role of angiotensin II-induced rapid response genes in the regulation of enzymes needed for aldosterone synthesis.</article-title>
            <source>J Mol Endocrinol</source>
            <year>2009</year>
            <month>Apr</month>
            <volume>42</volume>
            <issue>4</issue>
            <fpage>319</fpage>
            <page-range>319-30</page-range>
            <pub-id pub-id-type="pmid">19158234</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28375.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cano</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Miller</surname>
                <given-names>RT</given-names>
              </name>
              <name>
                <surname>Alpern</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Preisig</surname>
                <given-names>PA</given-names>
              </name>
            </person-group>
            <article-title>Angiotensin II stimulation of Na-H antiporter activity is cAMP independent in OKP cells.</article-title>
            <source>Am J Physiol</source>
            <year>1994</year>
            <month>Jun</month>
            <volume>266</volume>
            <issue>6 Pt 1</issue>
            <fpage>C1603</fpage>
            <page-range>C1603-8</page-range>
            <pub-id pub-id-type="pmid">8023891</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28375.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Reid</surname>
                <given-names>IA</given-names>
              </name>
            </person-group>
            <article-title>Interactions between ANG II, sympathetic nervous system, and baroreceptor reflexes in regulation of blood pressure.</article-title>
            <source>Am J Physiol</source>
            <year>1992</year>
            <month>Jun</month>
            <volume>262</volume>
            <issue>6 Pt 1</issue>
            <fpage>E763</fpage>
            <page-range>E763-78</page-range>
            <pub-id pub-id-type="pmid">1616014</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28375.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Qadri</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Culman</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Veltmar</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Maas</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Rascher</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Unger</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Angiotensin II-induced vasopressin release is mediated through alpha-1 adrenoceptors and angiotensin II AT1 receptors in the supraoptic nucleus.</article-title>
            <source>J Pharmacol Exp Ther</source>
            <year>1993</year>
            <month>Nov</month>
            <volume>267</volume>
            <issue>2</issue>
            <fpage>567</fpage>
            <page-range>567-74</page-range>
            <pub-id pub-id-type="pmid">8246129</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28375.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mehta</surname>
                <given-names>PK</given-names>
              </name>
              <name>
                <surname>Griendling</surname>
                <given-names>KK</given-names>
              </name>
            </person-group>
            <article-title>Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system.</article-title>
            <source>Am J Physiol Cell Physiol</source>
            <year>2007</year>
            <month>Jan</month>
            <volume>292</volume>
            <issue>1</issue>
            <fpage>C82</fpage>
            <page-range>C82-97</page-range>
            <pub-id pub-id-type="pmid">16870827</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28375.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rajagopalan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kurz</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>M&#x000fc;nzel</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Tarpey</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Freeman</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Griendling</surname>
                <given-names>KK</given-names>
              </name>
              <name>
                <surname>Harrison</surname>
                <given-names>DG</given-names>
              </name>
            </person-group>
            <article-title>Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone.</article-title>
            <source>J Clin Invest</source>
            <year>1996</year>
            <month>Apr</month>
            <day>15</day>
            <volume>97</volume>
            <issue>8</issue>
            <fpage>1916</fpage>
            <page-range>1916-23</page-range>
            <pub-id pub-id-type="pmid">8621776</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28375.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dzau</surname>
                <given-names>VJ</given-names>
              </name>
            </person-group>
            <article-title>Theodore Cooper Lecture: Tissue angiotensin and pathobiology of vascular disease: a unifying hypothesis.</article-title>
            <source>Hypertension</source>
            <year>2001</year>
            <month>Apr</month>
            <volume>37</volume>
            <issue>4</issue>
            <fpage>1047</fpage>
            <page-range>1047-52</page-range>
            <pub-id pub-id-type="pmid">11304501</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28375.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schieffer</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Schieffer</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Hilfiker-Kleiner</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Hilfiker</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kovanen</surname>
                <given-names>PT</given-names>
              </name>
              <name>
                <surname>Kaartinen</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Nussberger</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Harringer</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Drexler</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Expression of angiotensin II and interleukin 6 in human coronary atherosclerotic plaques: potential implications for inflammation and plaque instability.</article-title>
            <source>Circulation</source>
            <year>2000</year>
            <month>Mar</month>
            <day>28</day>
            <volume>101</volume>
            <issue>12</issue>
            <fpage>1372</fpage>
            <page-range>1372-8</page-range>
            <pub-id pub-id-type="pmid">10736279</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28375.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>AbdAlla</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lother</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Abdel-tawab</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Quitterer</surname>
                <given-names>U</given-names>
              </name>
            </person-group>
            <article-title>The angiotensin II AT2 receptor is an AT1 receptor antagonist.</article-title>
            <source>J Biol Chem</source>
            <year>2001</year>
            <month>Oct</month>
            <day>26</day>
            <volume>276</volume>
            <issue>43</issue>
            <fpage>39721</fpage>
            <page-range>39721-6</page-range>
            <pub-id pub-id-type="pmid">11507095</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28375.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ferrario</surname>
                <given-names>CM</given-names>
              </name>
            </person-group>
            <article-title>Role of angiotensin II in cardiovascular disease therapeutic implications of more than a century of research.</article-title>
            <source>J Renin Angiotensin Aldosterone Syst</source>
            <year>2006</year>
            <month>Mar</month>
            <volume>7</volume>
            <issue>1</issue>
            <fpage>3</fpage>
            <page-range>3-14</page-range>
            <pub-id pub-id-type="pmid">17083068</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28375.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Xu</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Han</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Zou</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Yu</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Shan</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Lum</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Liang</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Angiotensin II induces kidney inflammatory injury and fibrosis through binding to myeloid differentiation protein-2 (MD2).</article-title>
            <source>Sci Rep</source>
            <year>2017</year>
            <month>Mar</month>
            <day>21</day>
            <volume>7</volume>
            <fpage>44911</fpage>
            <pub-id pub-id-type="pmid">28322341</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28375.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Karnik</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Unal</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kemp</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Tirupula</surname>
                <given-names>KC</given-names>
              </name>
              <name>
                <surname>Eguchi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Vanderheyden</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Thomas</surname>
                <given-names>WG</given-names>
              </name>
            </person-group>
            <article-title>International Union of Basic and Clinical Pharmacology. XCIX. Angiotensin Receptors: Interpreters of Pathophysiological Angiotensinergic Stimuli [corrected].</article-title>
            <source>Pharmacol Rev</source>
            <year>2015</year>
            <month>Oct</month>
            <volume>67</volume>
            <issue>4</issue>
            <fpage>754</fpage>
            <page-range>754-819</page-range>
            <pub-id pub-id-type="pmid">26315714</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28375.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Carey</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>ZQ</given-names>
              </name>
              <name>
                <surname>Siragy</surname>
                <given-names>HM</given-names>
              </name>
            </person-group>
            <article-title>Role of the angiotensin type 2 receptor in the regulation of blood pressure and renal function.</article-title>
            <source>Hypertension</source>
            <year>2000</year>
            <month>Jan</month>
            <volume>35</volume>
            <issue>1 Pt 2</issue>
            <fpage>155</fpage>
            <page-range>155-63</page-range>
            <pub-id pub-id-type="pmid">10642292</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28375.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zhang</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Han</surname>
                <given-names>GW</given-names>
              </name>
              <name>
                <surname>Batyuk</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ishchenko</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>White</surname>
                <given-names>KL</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Sadybekov</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Zamlynny</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Rudd</surname>
                <given-names>MT</given-names>
              </name>
              <name>
                <surname>Hollenstein</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Tolstikova</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>White</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>Hunter</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Weierstall</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Babaoglu</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Moore</surname>
                <given-names>EL</given-names>
              </name>
              <name>
                <surname>Katz</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Shipman</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Garcia-Calvo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sharma</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sheth</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Soisson</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Stevens</surname>
                <given-names>RC</given-names>
              </name>
              <name>
                <surname>Katritch</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Cherezov</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>Structural basis for selectivity and diversity in angiotensin II receptors.</article-title>
            <source>Nature</source>
            <year>2017</year>
            <month>Apr</month>
            <day>20</day>
            <volume>544</volume>
            <issue>7650</issue>
            <fpage>327</fpage>
            <page-range>327-332</page-range>
            <pub-id pub-id-type="pmid">28379944</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28375.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kakar</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Sellers</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Devor</surname>
                <given-names>DC</given-names>
              </name>
              <name>
                <surname>Musgrove</surname>
                <given-names>LC</given-names>
              </name>
              <name>
                <surname>Neill</surname>
                <given-names>JD</given-names>
              </name>
            </person-group>
            <article-title>Angiotensin II type-1 receptor subtype cDNAs: differential tissue expression and hormonal regulation.</article-title>
            <source>Biochem Biophys Res Commun</source>
            <year>1992</year>
            <month>Mar</month>
            <day>31</day>
            <volume>183</volume>
            <issue>3</issue>
            <fpage>1090</fpage>
            <page-range>1090-6</page-range>
            <pub-id pub-id-type="pmid">1567388</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28375.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sumners</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Alleyne</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Rodr&#x000ed;guez</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Pioquinto</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Ludin</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Kar</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Winder</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Ortiz</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Krause</surname>
                <given-names>EG</given-names>
              </name>
              <name>
                <surname>de Kloet</surname>
                <given-names>AD</given-names>
              </name>
            </person-group>
            <article-title>Brain angiotensin type-1 and type-2 receptors: cellular locations under normal and hypertensive conditions.</article-title>
            <source>Hypertens Res</source>
            <year>2020</year>
            <month>Apr</month>
            <volume>43</volume>
            <issue>4</issue>
            <fpage>281</fpage>
            <page-range>281-295</page-range>
            <pub-id pub-id-type="pmid">31853042</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28375.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Iwanaga</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Kihara</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Takenaka</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kita</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Down-regulation of cardiac apelin system in hypertrophied and failing hearts: Possible role of angiotensin II-angiotensin type 1 receptor system.</article-title>
            <source>J Mol Cell Cardiol</source>
            <year>2006</year>
            <month>Nov</month>
            <volume>41</volume>
            <issue>5</issue>
            <fpage>798</fpage>
            <page-range>798-806</page-range>
            <pub-id pub-id-type="pmid">16919293</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28375.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Allen</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Zhuo</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Mendelsohn</surname>
                <given-names>FA</given-names>
              </name>
            </person-group>
            <article-title>Localization and function of angiotensin AT1 receptors.</article-title>
            <source>Am J Hypertens</source>
            <year>2000</year>
            <month>Jan</month>
            <volume>13</volume>
            <issue>1 Pt 2</issue>
            <fpage>31S</fpage>
            <page-range>31S-38S</page-range>
            <pub-id pub-id-type="pmid">10678286</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28375.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Eguchi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kawai</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Scalia</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Rizzo</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>Understanding Angiotensin II Type 1 Receptor Signaling in Vascular Pathophysiology.</article-title>
            <source>Hypertension</source>
            <year>2018</year>
            <month>May</month>
            <volume>71</volume>
            <issue>5</issue>
            <fpage>804</fpage>
            <page-range>804-810</page-range>
            <pub-id pub-id-type="pmid">29581215</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28375.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kaschina</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Unger</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Angiotensin AT1/AT2 receptors: regulation, signalling and function.</article-title>
            <source>Blood Press</source>
            <year>2003</year>
            <volume>12</volume>
            <issue>2</issue>
            <fpage>70</fpage>
            <page-range>70-88</page-range>
            <pub-id pub-id-type="pmid">12797627</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28375.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Naito</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Ma</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Zuo</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Tang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Han</surname>
                <given-names>JY</given-names>
              </name>
              <name>
                <surname>Kon</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Fogo</surname>
                <given-names>AB</given-names>
              </name>
            </person-group>
            <article-title>Angiotensin type 2 receptor actions contribute to angiotensin type 1 receptor blocker effects on kidney fibrosis.</article-title>
            <source>Am J Physiol Renal Physiol</source>
            <year>2010</year>
            <month>Mar</month>
            <volume>298</volume>
            <issue>3</issue>
            <fpage>F683</fpage>
            <page-range>F683-91</page-range>
            <pub-id pub-id-type="pmid">20042458</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28375.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Billet</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Aguilar</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Baudry</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Clauser</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Role of angiotensin II AT1 receptor activation in cardiovascular diseases.</article-title>
            <source>Kidney Int</source>
            <year>2008</year>
            <month>Dec</month>
            <volume>74</volume>
            <issue>11</issue>
            <fpage>1379</fpage>
            <page-range>1379-84</page-range>
            <pub-id pub-id-type="pmid">18650793</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28375.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lazard</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Briend-Sutren</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Villageois</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Mattei</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Strosberg</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>Nahmias</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Molecular characterization and chromosome localization of a human angiotensin II AT2 receptor gene highly expressed in fetal tissues.</article-title>
            <source>Recept Channels</source>
            <year>1994</year>
            <volume>2</volume>
            <issue>4</issue>
            <fpage>271</fpage>
            <page-range>271-80</page-range>
            <pub-id pub-id-type="pmid">7719706</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28375.r43">
          <label>43</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ozono</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>ZQ</given-names>
              </name>
              <name>
                <surname>Moore</surname>
                <given-names>AF</given-names>
              </name>
              <name>
                <surname>Inagami</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Siragy</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Carey</surname>
                <given-names>RM</given-names>
              </name>
            </person-group>
            <article-title>Expression of the subtype 2 angiotensin (AT2) receptor protein in rat kidney.</article-title>
            <source>Hypertension</source>
            <year>1997</year>
            <month>Nov</month>
            <volume>30</volume>
            <issue>5</issue>
            <fpage>1238</fpage>
            <page-range>1238-46</page-range>
            <pub-id pub-id-type="pmid">9369282</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28375.r44">
          <label>44</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tsutsumi</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Saavedra</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <article-title>Characterization and development of angiotensin II receptor subtypes (AT1 and AT2) in rat brain.</article-title>
            <source>Am J Physiol</source>
            <year>1991</year>
            <month>Jul</month>
            <volume>261</volume>
            <issue>1 Pt 2</issue>
            <fpage>R209</fpage>
            <page-range>R209-16</page-range>
            <pub-id pub-id-type="pmid">1858948</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28375.r45">
          <label>45</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wang</surname>
                <given-names>ZQ</given-names>
              </name>
              <name>
                <surname>Moore</surname>
                <given-names>AF</given-names>
              </name>
              <name>
                <surname>Ozono</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Siragy</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Carey</surname>
                <given-names>RM</given-names>
              </name>
            </person-group>
            <article-title>Immunolocalization of subtype 2 angiotensin II (AT2) receptor protein in rat heart.</article-title>
            <source>Hypertension</source>
            <year>1998</year>
            <month>Jul</month>
            <volume>32</volume>
            <issue>1</issue>
            <fpage>78</fpage>
            <page-range>78-83</page-range>
            <pub-id pub-id-type="pmid">9674641</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28375.r46">
          <label>46</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Namsolleck</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Recarti</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Foulquier</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Steckelings</surname>
                <given-names>UM</given-names>
              </name>
              <name>
                <surname>Unger</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>AT(2) receptor and tissue injury: therapeutic implications.</article-title>
            <source>Curr Hypertens Rep</source>
            <year>2014</year>
            <month>Feb</month>
            <volume>16</volume>
            <issue>2</issue>
            <fpage>416</fpage>
            <pub-id pub-id-type="pmid">24414230</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28375.r47">
          <label>47</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Carey</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Siragy</surname>
                <given-names>HM</given-names>
              </name>
            </person-group>
            <article-title>Newly recognized components of the renin-angiotensin system: potential roles in cardiovascular and renal regulation.</article-title>
            <source>Endocr Rev</source>
            <year>2003</year>
            <month>Jun</month>
            <volume>24</volume>
            <issue>3</issue>
            <fpage>261</fpage>
            <page-range>261-71</page-range>
            <pub-id pub-id-type="pmid">12788798</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28375.r48">
          <label>48</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Siragy</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Inagami</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Ichiki</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Carey</surname>
                <given-names>RM</given-names>
              </name>
            </person-group>
            <article-title>Sustained hypersensitivity to angiotensin II and its mechanism in mice lacking the subtype-2 (AT2) angiotensin receptor.</article-title>
            <source>Proc Natl Acad Sci U S A</source>
            <year>1999</year>
            <month>May</month>
            <day>25</day>
            <volume>96</volume>
            <issue>11</issue>
            <fpage>6506</fpage>
            <page-range>6506-10</page-range>
            <pub-id pub-id-type="pmid">10339618</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28375.r49">
          <label>49</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sampson</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Moritz</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Jones</surname>
                <given-names>ES</given-names>
              </name>
              <name>
                <surname>Flower</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Widdop</surname>
                <given-names>RE</given-names>
              </name>
              <name>
                <surname>Denton</surname>
                <given-names>KM</given-names>
              </name>
            </person-group>
            <article-title>Enhanced angiotensin II type 2 receptor mechanisms mediate decreases in arterial pressure attributable to chronic low-dose angiotensin II in female rats.</article-title>
            <source>Hypertension</source>
            <year>2008</year>
            <month>Oct</month>
            <volume>52</volume>
            <issue>4</issue>
            <fpage>666</fpage>
            <page-range>666-71</page-range>
            <pub-id pub-id-type="pmid">18711010</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28375.r50">
          <label>50</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Williams</surname>
                <given-names>GH</given-names>
              </name>
            </person-group>
            <article-title>Aldosterone biosynthesis, regulation, and classical mechanism of action.</article-title>
            <source>Heart Fail Rev</source>
            <year>2005</year>
            <month>Jan</month>
            <volume>10</volume>
            <issue>1</issue>
            <fpage>7</fpage>
            <page-range>7-13</page-range>
            <pub-id pub-id-type="pmid">15947886</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28375.r51">
          <label>51</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Quinn</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Williams</surname>
                <given-names>GH</given-names>
              </name>
            </person-group>
            <article-title>Regulation of aldosterone secretion.</article-title>
            <source>Annu Rev Physiol</source>
            <year>1988</year>
            <volume>50</volume>
            <fpage>409</fpage>
            <page-range>409-26</page-range>
            <pub-id pub-id-type="pmid">3288099</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28375.r52">
          <label>52</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Arriza</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Weinberger</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Cerelli</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Glaser</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Handelin</surname>
                <given-names>BL</given-names>
              </name>
              <name>
                <surname>Housman</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Evans</surname>
                <given-names>RM</given-names>
              </name>
            </person-group>
            <article-title>Cloning of human mineralocorticoid receptor complementary DNA: structural and functional kinship with the glucocorticoid receptor.</article-title>
            <source>Science</source>
            <year>1987</year>
            <month>Jul</month>
            <day>17</day>
            <volume>237</volume>
            <issue>4812</issue>
            <fpage>268</fpage>
            <page-range>268-75</page-range>
            <pub-id pub-id-type="pmid">3037703</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28375.r53">
          <label>53</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Holst</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Soldin</surname>
                <given-names>OP</given-names>
              </name>
              <name>
                <surname>Guo</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Soldin</surname>
                <given-names>SJ</given-names>
              </name>
            </person-group>
            <article-title>Steroid hormones: relevance and measurement in the clinical laboratory.</article-title>
            <source>Clin Lab Med</source>
            <year>2004</year>
            <month>Mar</month>
            <volume>24</volume>
            <issue>1</issue>
            <fpage>105</fpage>
            <page-range>105-18</page-range>
            <pub-id pub-id-type="pmid">15157559</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28375.r54">
          <label>54</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>McCormick</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Bhalla</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Pao</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Pearce</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>SGK1: a rapid aldosterone-induced regulator of renal sodium reabsorption.</article-title>
            <source>Physiology (Bethesda)</source>
            <year>2005</year>
            <month>Apr</month>
            <volume>20</volume>
            <fpage>134</fpage>
            <page-range>134-9</page-range>
            <pub-id pub-id-type="pmid">15772302</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28375.r55">
          <label>55</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Summa</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Mordasini</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Roger</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Bens</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Martin</surname>
                <given-names>PY</given-names>
              </name>
              <name>
                <surname>Vandewalle</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Verrey</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>F&#x000e9;raille</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Short term effect of aldosterone on Na,K-ATPase cell surface expression in kidney collecting duct cells.</article-title>
            <source>J Biol Chem</source>
            <year>2001</year>
            <month>Dec</month>
            <day>14</day>
            <volume>276</volume>
            <issue>50</issue>
            <fpage>47087</fpage>
            <page-range>47087-93</page-range>
            <pub-id pub-id-type="pmid">11598118</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28375.r56">
          <label>56</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>MacKenzie</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Clark</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Fraser</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>G&#x000f3;mez-S&#x000e1;nchez</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Connell</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Davies</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Expression of 11beta-hydroxylase and aldosterone synthase genes in the rat brain.</article-title>
            <source>J Mol Endocrinol</source>
            <year>2000</year>
            <month>Jun</month>
            <volume>24</volume>
            <issue>3</issue>
            <fpage>321</fpage>
            <page-range>321-8</page-range>
            <pub-id pub-id-type="pmid">10828825</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28375.r57">
          <label>57</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fuller</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Yao</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Young</surname>
                <given-names>MJ</given-names>
              </name>
            </person-group>
            <article-title>Mechanisms of ligand specificity of the mineralocorticoid receptor.</article-title>
            <source>J Endocrinol</source>
            <year>2012</year>
            <month>Apr</month>
            <volume>213</volume>
            <issue>1</issue>
            <fpage>15</fpage>
            <page-range>15-24</page-range>
            <pub-id pub-id-type="pmid">22159507</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28375.r58">
          <label>58</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Geerling</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Loewy</surname>
                <given-names>AD</given-names>
              </name>
            </person-group>
            <article-title>Aldosterone in the brain.</article-title>
            <source>Am J Physiol Renal Physiol</source>
            <year>2009</year>
            <month>Sep</month>
            <volume>297</volume>
            <issue>3</issue>
            <fpage>F559</fpage>
            <page-range>F559-76</page-range>
            <pub-id pub-id-type="pmid">19261742</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28375.r59">
          <label>59</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Xue</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Roncari</surname>
                <given-names>CF</given-names>
              </name>
              <name>
                <surname>Guo</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>AK</given-names>
              </name>
            </person-group>
            <article-title>Aldosterone acting through the central nervous system sensitizes angiotensin II-induced hypertension.</article-title>
            <source>Hypertension</source>
            <year>2012</year>
            <month>Oct</month>
            <volume>60</volume>
            <issue>4</issue>
            <fpage>1023</fpage>
            <page-range>1023-30</page-range>
            <pub-id pub-id-type="pmid">22949534</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28375.r60">
          <label>60</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Remuzzi</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Perico</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Macia</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ruggenenti</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>The role of renin-angiotensin-aldosterone system in the progression of chronic kidney disease.</article-title>
            <source>Kidney Int Suppl</source>
            <year>2005</year>
            <month>Dec</month>
            <issue>99</issue>
            <fpage>S57</fpage>
            <page-range>S57-65</page-range>
            <pub-id pub-id-type="pmid">16336578</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28375.r61">
          <label>61</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Orsborne</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Chaggar</surname>
                <given-names>PS</given-names>
              </name>
              <name>
                <surname>Shaw</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Williams</surname>
                <given-names>SG</given-names>
              </name>
            </person-group>
            <article-title>The renin-angiotensin-aldosterone system in heart failure for the non-specialist: the past, the present and the future.</article-title>
            <source>Postgrad Med J</source>
            <year>2017</year>
            <month>Jan</month>
            <volume>93</volume>
            <issue>1095</issue>
            <fpage>29</fpage>
            <page-range>29-37</page-range>
            <pub-id pub-id-type="pmid">27671772</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28375.r62">
          <label>62</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schmieder</surname>
                <given-names>RE</given-names>
              </name>
              <name>
                <surname>Hilgers</surname>
                <given-names>KF</given-names>
              </name>
              <name>
                <surname>Schlaich</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Schmidt</surname>
                <given-names>BM</given-names>
              </name>
            </person-group>
            <article-title>Renin-angiotensin system and cardiovascular risk.</article-title>
            <source>Lancet</source>
            <year>2007</year>
            <month>Apr</month>
            <day>07</day>
            <volume>369</volume>
            <issue>9568</issue>
            <fpage>1208</fpage>
            <page-range>1208-19</page-range>
            <pub-id pub-id-type="pmid">17416265</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28375.r63">
          <label>63</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Manrique</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Lastra</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Gardner</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sowers</surname>
                <given-names>JR</given-names>
              </name>
            </person-group>
            <article-title>The renin angiotensin aldosterone system in hypertension: roles of insulin resistance and oxidative stress.</article-title>
            <source>Med Clin North Am</source>
            <year>2009</year>
            <month>May</month>
            <volume>93</volume>
            <issue>3</issue>
            <fpage>569</fpage>
            <page-range>569-82</page-range>
            <pub-id pub-id-type="pmid">19427492</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28375.r64">
          <label>64</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ferrari</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>RAAS inhibition and mortality in hypertension.</article-title>
            <source>Glob Cardiol Sci Pract</source>
            <year>2013</year>
            <volume>2013</volume>
            <issue>3</issue>
            <fpage>269</fpage>
            <page-range>269-78</page-range>
            <pub-id pub-id-type="pmid">24689028</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28375.r65">
          <label>65</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rossi</surname>
                <given-names>GP</given-names>
              </name>
            </person-group>
            <article-title>Primary Aldosteronism: JACC State-of-the-Art Review.</article-title>
            <source>J Am Coll Cardiol</source>
            <year>2019</year>
            <month>Dec</month>
            <day>03</day>
            <volume>74</volume>
            <issue>22</issue>
            <fpage>2799</fpage>
            <page-range>2799-2811</page-range>
            <pub-id pub-id-type="pmid">31779795</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28375.r66">
          <label>66</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cohen</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Cohen</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Herman</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Leppert</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Byrd</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Bhalla</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>Testing for Primary Aldosteronism and Mineralocorticoid Receptor Antagonist Use Among U.S. Veterans : A Retrospective Cohort Study.</article-title>
            <source>Ann Intern Med</source>
            <year>2021</year>
            <month>Mar</month>
            <volume>174</volume>
            <issue>3</issue>
            <fpage>289</fpage>
            <page-range>289-297</page-range>
            <pub-id pub-id-type="pmid">33370170</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28375.r67">
          <label>67</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Parving</surname>
                <given-names>HH</given-names>
              </name>
              <name>
                <surname>Brenner</surname>
                <given-names>BM</given-names>
              </name>
              <name>
                <surname>McMurray</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>de Zeeuw</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Haffner</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Solomon</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Chaturvedi</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Persson</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Desai</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Nicolaides</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Richard</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Xiang</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Brunel</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Pfeffer</surname>
                <given-names>MA</given-names>
              </name>
              <collab>ALTITUDE Investigators</collab>
            </person-group>
            <article-title>Cardiorenal end points in a trial of aliskiren for type 2 diabetes.</article-title>
            <source>N Engl J Med</source>
            <year>2012</year>
            <month>Dec</month>
            <day>06</day>
            <volume>367</volume>
            <issue>23</issue>
            <fpage>2204</fpage>
            <page-range>2204-13</page-range>
            <pub-id pub-id-type="pmid">23121378</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28375.r68">
          <label>68</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Heerspink</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Persson</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Brenner</surname>
                <given-names>BM</given-names>
              </name>
              <name>
                <surname>Chaturvedi</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Brunel</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>McMurray</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Desai</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Solomon</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Pfeffer</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Parving</surname>
                <given-names>HH</given-names>
              </name>
              <name>
                <surname>de Zeeuw</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Renal outcomes with aliskiren in patients with type 2 diabetes: a prespecified secondary analysis of the ALTITUDE randomised controlled trial.</article-title>
            <source>Lancet Diabetes Endocrinol</source>
            <year>2016</year>
            <month>Apr</month>
            <volume>4</volume>
            <issue>4</issue>
            <fpage>309</fpage>
            <page-range>309-17</page-range>
            <pub-id pub-id-type="pmid">26774608</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28375.r69">
          <label>69</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>K&#x000f8;ber</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Torp-Pedersen</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Carlsen</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Bagger</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Eliasen</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Lyngborg</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Videbaek</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Cole</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Auclert</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Pauly</surname>
                <given-names>NC</given-names>
              </name>
            </person-group>
            <article-title>A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group.</article-title>
            <source>N Engl J Med</source>
            <year>1995</year>
            <month>Dec</month>
            <day>21</day>
            <volume>333</volume>
            <issue>25</issue>
            <fpage>1670</fpage>
            <page-range>1670-6</page-range>
            <pub-id pub-id-type="pmid">7477219</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28375.r70">
          <label>70</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pfeffer</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Braunwald</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Moy&#x000e9;</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Basta</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Cuddy</surname>
                <given-names>TE</given-names>
              </name>
              <name>
                <surname>Davis</surname>
                <given-names>BR</given-names>
              </name>
              <name>
                <surname>Geltman</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Goldman</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Flaker</surname>
                <given-names>GC</given-names>
              </name>
            </person-group>
            <article-title>Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators.</article-title>
            <source>N Engl J Med</source>
            <year>1992</year>
            <month>Sep</month>
            <day>03</day>
            <volume>327</volume>
            <issue>10</issue>
            <fpage>669</fpage>
            <page-range>669-77</page-range>
            <pub-id pub-id-type="pmid">1386652</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28375.r71">
          <label>71</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lewis</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Hunsicker</surname>
                <given-names>LG</given-names>
              </name>
              <name>
                <surname>Bain</surname>
                <given-names>RP</given-names>
              </name>
              <name>
                <surname>Rohde</surname>
                <given-names>RD</given-names>
              </name>
            </person-group>
            <article-title>The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group.</article-title>
            <source>N Engl J Med</source>
            <year>1993</year>
            <month>Nov</month>
            <day>11</day>
            <volume>329</volume>
            <issue>20</issue>
            <fpage>1456</fpage>
            <page-range>1456-62</page-range>
            <pub-id pub-id-type="pmid">8413456</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28375.r72">
          <label>72</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kamper</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Strandgaard</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Leyssac</surname>
                <given-names>PP</given-names>
              </name>
            </person-group>
            <article-title>Effect of enalapril on the progression of chronic renal failure. A randomized controlled trial.</article-title>
            <source>Am J Hypertens</source>
            <year>1992</year>
            <month>Jul</month>
            <volume>5</volume>
            <issue>7</issue>
            <fpage>423</fpage>
            <page-range>423-30</page-range>
            <pub-id pub-id-type="pmid">1637513</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28375.r73">
          <label>73</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Maschio</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Alberti</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Janin</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Locatelli</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Mann</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Motolese</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ponticelli</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Ritz</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Zucchelli</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group.</article-title>
            <source>N Engl J Med</source>
            <year>1996</year>
            <month>Apr</month>
            <day>11</day>
            <volume>334</volume>
            <issue>15</issue>
            <fpage>939</fpage>
            <page-range>939-45</page-range>
            <pub-id pub-id-type="pmid">8596594</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28375.r74">
          <label>74</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cohn</surname>
                <given-names>JN</given-names>
              </name>
              <name>
                <surname>Tognoni</surname>
                <given-names>G</given-names>
              </name>
              <collab>Valsartan Heart Failure Trial Investigators</collab>
            </person-group>
            <article-title>A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure.</article-title>
            <source>N Engl J Med</source>
            <year>2001</year>
            <month>Dec</month>
            <day>06</day>
            <volume>345</volume>
            <issue>23</issue>
            <fpage>1667</fpage>
            <page-range>1667-75</page-range>
            <pub-id pub-id-type="pmid">11759645</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28375.r75">
          <label>75</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pitt</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Segal</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Martinez</surname>
                <given-names>FA</given-names>
              </name>
              <name>
                <surname>Meurers</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Cowley</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Thomas</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Deedwania</surname>
                <given-names>PC</given-names>
              </name>
              <name>
                <surname>Ney</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Snavely</surname>
                <given-names>DB</given-names>
              </name>
              <name>
                <surname>Chang</surname>
                <given-names>PI</given-names>
              </name>
            </person-group>
            <article-title>Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE).</article-title>
            <source>Lancet</source>
            <year>1997</year>
            <month>Mar</month>
            <day>15</day>
            <volume>349</volume>
            <issue>9054</issue>
            <fpage>747</fpage>
            <page-range>747-52</page-range>
            <pub-id pub-id-type="pmid">9074572</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28375.r76">
          <label>76</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Young</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Dunlap</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Pfeffer</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Probstfield</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Cohen-Solal</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Dietz</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Granger</surname>
                <given-names>CB</given-names>
              </name>
              <name>
                <surname>Hradec</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kuch</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>McKelvie</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>McMurray</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Michelson</surname>
                <given-names>EL</given-names>
              </name>
              <name>
                <surname>Olofsson</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Ostergren</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Held</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Solomon</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Yusuf</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Swedberg</surname>
                <given-names>K</given-names>
              </name>
              <collab>Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) Investigators and Committees</collab>
            </person-group>
            <article-title>Mortality and morbidity reduction with Candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trials.</article-title>
            <source>Circulation</source>
            <year>2004</year>
            <month>Oct</month>
            <day>26</day>
            <volume>110</volume>
            <issue>17</issue>
            <fpage>2618</fpage>
            <page-range>2618-26</page-range>
            <pub-id pub-id-type="pmid">15492298</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28375.r77">
          <label>77</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brenner</surname>
                <given-names>BM</given-names>
              </name>
              <name>
                <surname>Cooper</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>de Zeeuw</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Keane</surname>
                <given-names>WF</given-names>
              </name>
              <name>
                <surname>Mitch</surname>
                <given-names>WE</given-names>
              </name>
              <name>
                <surname>Parving</surname>
                <given-names>HH</given-names>
              </name>
              <name>
                <surname>Remuzzi</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Snapinn</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Shahinfar</surname>
                <given-names>S</given-names>
              </name>
              <collab>RENAAL Study Investigators</collab>
            </person-group>
            <article-title>Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.</article-title>
            <source>N Engl J Med</source>
            <year>2001</year>
            <month>Sep</month>
            <day>20</day>
            <volume>345</volume>
            <issue>12</issue>
            <fpage>861</fpage>
            <page-range>861-9</page-range>
            <pub-id pub-id-type="pmid">11565518</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28375.r78">
          <label>78</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yoo</surname>
                <given-names>TH</given-names>
              </name>
              <name>
                <surname>Hong</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Shin</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>DK</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Han</surname>
                <given-names>SY</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Won</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Kang</surname>
                <given-names>YS</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Han</surname>
                <given-names>BG</given-names>
              </name>
              <name>
                <surname>Na</surname>
                <given-names>KR</given-names>
              </name>
              <name>
                <surname>Hur</surname>
                <given-names>KY</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>YJ</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>The FimAsartaN proTeinuriA SusTaIned reduCtion in comparison with losartan in diabetic chronic kidney disease (FANTASTIC) trial.</article-title>
            <source>Hypertens Res</source>
            <year>2022</year>
            <month>Dec</month>
            <volume>45</volume>
            <issue>12</issue>
            <fpage>2008</fpage>
            <page-range>2008-2017</page-range>
            <pub-id pub-id-type="pmid">36123398</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28375.r79">
          <label>79</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lewis</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Hunsicker</surname>
                <given-names>LG</given-names>
              </name>
              <name>
                <surname>Clarke</surname>
                <given-names>WR</given-names>
              </name>
              <name>
                <surname>Berl</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Pohl</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Lewis</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Ritz</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Atkins</surname>
                <given-names>RC</given-names>
              </name>
              <name>
                <surname>Rohde</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Raz</surname>
                <given-names>I</given-names>
              </name>
              <collab>Collaborative Study Group</collab>
            </person-group>
            <article-title>Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.</article-title>
            <source>N Engl J Med</source>
            <year>2001</year>
            <month>Sep</month>
            <day>20</day>
            <volume>345</volume>
            <issue>12</issue>
            <fpage>851</fpage>
            <page-range>851-60</page-range>
            <pub-id pub-id-type="pmid">11565517</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28375.r80">
          <label>80</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pitt</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Zannad</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Remme</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Cody</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Castaigne</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Perez</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Palensky</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Wittes</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.</article-title>
            <source>N Engl J Med</source>
            <year>1999</year>
            <month>Sep</month>
            <day>02</day>
            <volume>341</volume>
            <issue>10</issue>
            <fpage>709</fpage>
            <page-range>709-17</page-range>
            <pub-id pub-id-type="pmid">10471456</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28375.r81">
          <label>81</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zannad</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>McMurray</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Krum</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>van Veldhuisen</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Swedberg</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Shi</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Vincent</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Pocock</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Pitt</surname>
                <given-names>B</given-names>
              </name>
              <collab>EMPHASIS-HF Study Group</collab>
            </person-group>
            <article-title>Eplerenone in patients with systolic heart failure and mild symptoms.</article-title>
            <source>N Engl J Med</source>
            <year>2011</year>
            <month>Jan</month>
            <day>06</day>
            <volume>364</volume>
            <issue>1</issue>
            <fpage>11</fpage>
            <page-range>11-21</page-range>
            <pub-id pub-id-type="pmid">21073363</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28375.r82">
          <label>82</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pitt</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Filippatos</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Agarwal</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Anker</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Bakris</surname>
                <given-names>GL</given-names>
              </name>
              <name>
                <surname>Rossing</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Joseph</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kolkhof</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Nowack</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Schloemer</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Ruilope</surname>
                <given-names>LM</given-names>
              </name>
              <collab>FIGARO-DKD Investigators</collab>
            </person-group>
            <article-title>Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes.</article-title>
            <source>N Engl J Med</source>
            <year>2021</year>
            <month>Dec</month>
            <day>09</day>
            <volume>385</volume>
            <issue>24</issue>
            <fpage>2252</fpage>
            <page-range>2252-2263</page-range>
            <pub-id pub-id-type="pmid">34449181</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28375.r83">
          <label>83</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bakris</surname>
                <given-names>GL</given-names>
              </name>
              <name>
                <surname>Agarwal</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Anker</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Pitt</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Ruilope</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Rossing</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Kolkhof</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Nowack</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Schloemer</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Joseph</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Filippatos</surname>
                <given-names>G</given-names>
              </name>
              <collab>FIDELIO-DKD Investigators</collab>
            </person-group>
            <article-title>Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes.</article-title>
            <source>N Engl J Med</source>
            <year>2020</year>
            <month>Dec</month>
            <day>03</day>
            <volume>383</volume>
            <issue>23</issue>
            <fpage>2219</fpage>
            <page-range>2219-2229</page-range>
            <pub-id pub-id-type="pmid">33264825</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28375.r84">
          <label>84</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Freeman</surname>
                <given-names>MW</given-names>
              </name>
              <name>
                <surname>Halvorsen</surname>
                <given-names>YD</given-names>
              </name>
              <name>
                <surname>Marshall</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Pater</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Isaacsohn</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Pearce</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Murphy</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Alp</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Srivastava</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bhatt</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>MJ</given-names>
              </name>
              <collab>BrigHTN Investigators</collab>
            </person-group>
            <article-title>Phase 2 Trial of Baxdrostat for Treatment-Resistant Hypertension.</article-title>
            <source>N Engl J Med</source>
            <year>2023</year>
            <month>Feb</month>
            <day>02</day>
            <volume>388</volume>
            <issue>5</issue>
            <fpage>395</fpage>
            <page-range>395-405</page-range>
            <pub-id pub-id-type="pmid">36342143</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28375.r85">
          <label>85</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hricik</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Dunn</surname>
                <given-names>MJ</given-names>
              </name>
            </person-group>
            <article-title>Angiotensin-converting enzyme inhibitor-induced renal failure: causes, consequences, and diagnostic uses.</article-title>
            <source>J Am Soc Nephrol</source>
            <year>1990</year>
            <month>Dec</month>
            <volume>1</volume>
            <issue>6</issue>
            <fpage>845</fpage>
            <page-range>845-58</page-range>
            <pub-id pub-id-type="pmid">2103846</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28375.r86">
          <label>86</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Murphy</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Wong</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Bezuhly</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Modulation of angiotensin II signaling in the prevention of fibrosis.</article-title>
            <source>Fibrogenesis Tissue Repair</source>
            <year>2015</year>
            <volume>8</volume>
            <fpage>7</fpage>
            <pub-id pub-id-type="pmid">25949522</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28375.r87">
          <label>87</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nagai</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Nitta</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kanasaki</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Koya</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Kanasaki</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>The biological significance of angiotensin-converting enzyme inhibition to combat kidney fibrosis.</article-title>
            <source>Clin Exp Nephrol</source>
            <year>2015</year>
            <month>Feb</month>
            <volume>19</volume>
            <issue>1</issue>
            <fpage>65</fpage>
            <page-range>65-74</page-range>
            <pub-id pub-id-type="pmid">24975544</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
